Immune dysregulation in Good’s syndrome: Mechanisms, autoantibodies, and therapeutic perspectives

Good’s Syndrome is an infrequent yet profoundly instructive disorder within the field of clinical immunology. Defined by the concurrence of thymoma, hypogammaglobulinemia, and cytopenias, it embodies a fascinating overlap of immunodeficiency and autoimmunity. While modern research has uncovered a landscape of immune irregularities (such as autoantibodies against key cytokines including IFN-alpha, IL-6, and GM-CSF) the precise sequence of pathogenic events and the natural disease progression remain elusive. Studies increasingly highlight profound immune dysregulation affecting both innate and adaptive pathways, with autoimmunity implicated as a potential catalyst for bone marrow failure. Despite these advances, the rarity of Good’s Syndrome and diversity of clinical presentations have limited deep mechanistic insights and hampered consensus on optimal therapeutic interventions.Recent investigations utilizing advanced immunophenotyping and molecular characterization have begun to dissect the complex cellular signaling and autoantibody networks at play. However, key questions persist regarding the initial triggers of autoimmunity, the roles of the thymic environment, and the variability in disease course leading to irreversible bone marrow aplasia. While clinical efforts including thymic transplantation, bone marrow transplantation, and novel biological therapies show potential, there remains no established standard of care, and few systematic studies address their efficacy or comparative outcomes. This underscores both the significance and the challenge of achieving precise diagnosis, personalized management, and improved prognostication for affected patients.This Research Topic aims to unravel the molecular and cellular foundations of Good’s Syndrome, elucidating the interplay between thymoma, immune homeostasis, autoantibody formation, and hematological failure. By attracting multidisciplinary research and collaborative clinical analysis, the goal is to clarify disease mechanisms, natural history, and to assess promising and emerging therapies that could enhance patient outcomes and serve as a paradigm for other immune-mediated conditions.Focusing on the unique interface of immunodeficiency, autoimmunity, and bone marrow failure in Good’s Syndrome, this Research Topic welcomes contributions spanning basic, translational, and clinical research while excluding unrelated immunopathologies. To gather further insights into this complex disorder, we welcome articles addressing, but not limited to, the following themes:- Mechanisms of immune dysregulation and autoantibody production in Good’s Syndrome- Cytokine targeting and signaling pathway defects- The role of thymoma in shaping immune homeostasis and pathology- Clinical characterization and evolution of bone marrow failure- Comparative studies on therapeutic interventions, including thymic and bone marrow transplantation and biologics- Novel biomarkers and approaches for diagnosis, prognosis, and disease monitoringArticle types suitable for this Research Topic include Original Research, Review, Mini Review, Case Report, Opinion, Perspective, Methods, and Short Communication. Topic editors: Roberto Paganelli, Paola Parronchi Source: https://www.frontiersin.org/research-topics/75451/immune-dysregulation-in-goods-syndrome-mechanisms-autoantibodies-and-therapeutic-perspectives